search
Back to results

Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors (DEMFOS)

Primary Purpose

Frailty, Sarcopenic Obesity, Aging

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Lifestyle therapy
Metformin Hydrochloride
Placebo
Healthy Lifesylte
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frailty

Eligibility Criteria

65 Years - 85 Years (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI = or > 30 kg/m2
  • Stable body weight (plus/minus 2 kg) during the past 6 months
  • Sedentary (regular exercise <1 h/wk or <2 x/wk for the last 6 months)
  • Willing to provide informed consent

Exclusion Criteria:

  • Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, or use of metformin, in which exercise, dietary restrictions, or metformin are contraindicated, or that would interfere with interpretation of results
  • Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstable disease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonary disease requiring steroid pills or the use of supplemental oxygen) that would contraindicate exercise or dietary restriction
  • Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, active rheumatoid arthritis) disease or impairments that would contraindicate participation in exercise
  • Renal impairment as defined by an estimated glomerular filtration rate (eGFR of less than 30 mL/min/1.73 m2) in which metformin is contraindicated
  • Other significant co-morbid disease that would impair ability to participate in the exercise intervention (e.g. severe psychiatric disorder [e.g. bipolar, schizophrenia], excess alcohol use [>14 drinks per week])
  • Severe visual or hearing impairments that would interfere with following directions
  • Significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State Exam (i.e. MMSE score <24)69
  • Uncontrolled hypertension (BP>160/90 mm Hg)
  • History of malignancy during the past 5 years (except non-melanoma skin cancers)
  • Current use of bone acting drugs (e.g. use of estrogen, or androgen containing compound,raloxifene, calcitonin, parathyroid hormone during the past year or bisphosphonates during the last two years)
  • Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragility fractures
  • Known history of diabetes mellitus or any of the following:

    • fasting blood glucose of 126 mg/dl, 2-h blood glucose 200 mg/dl in the OGTT, or HbA1c of 6.5% or >
  • Terminal illness with life expectancy less than 12 months, as determined by a physician
  • Use of any drugs or natural products designed to induce weight loss within past three months
  • History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men)
  • Positive exercise stress test for ischemia or any indication for early termination of exercise stress testing
  • Taking metformin or any other glucose lowering drug
  • Lives outside of the study site or is planning to move out of the area in the next 2 years

Sites / Locations

  • Michael E. DeBakey VA Medical Center, Houston, TXRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

Active Comparator

Arm Label

Lifestyle Therapy plus Metformin

Lifestyle Therapy plus Placebo

Healthy lifestyle plus Metformin

Arm Description

Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid

Diet-induced weight loss and Exercise Training plus Placebo

Healthy lifestyle and Metformin 1 gm bid

Outcomes

Primary Outcome Measures

Change in the modified Physical Performance Test (PPT)
The Physical Performance Test includes seven standardized tasks (walking 15.2 m [50 ft], putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg test) plus two additional tasks (going up and down four flights of stairs and making a 360-degree turn). The score for each task ranges from 0 to 4, with higher scores indicating better physical performance; a perfect score would be 36.

Secondary Outcome Measures

Change in muscle strength
Assessed by biodex dynamometer and1-repetition maximum
Change in dynamic balance
Assessed by the obstacle course
Change in static balance
Assessed by one leg stance
Change in gait speed
Assessed by time need to walk 25 ft
Change in peak aerobic power
Assessed by indirect calorimetry during a graded exercise test
Change in lean body mass
Assessed by dual-energy x-ray absorptiometry (DXA)
Chang in body fat
Assessed by DXA
Change in thigh muscle
Assessed by magnetic resonance imaging (MRI)
Change in thigh fat
Assessed by MRI
Change in muscle quality
Assessed by ratio of skeletal strength per unit of skeletal muscle
Change in bone microarchitecture
Assessed by high-resolution peripheral quantitative computed tomograph (HR-pQCT)
Change in bone strength
Assessed by finite-element analyses
Change in hip, lumbar spine, and wrist bone mineral density (BMD)
Assessed by DXA
Change in wrist and tibial cortical and trabecular BMD
Assessed by HR-pQCT
Change in serum C-telopeptide
Assessed by immunoassay
Change in subjective ability to function
Assessed by Functional Status Questionnaire (score range: 0 to 36 with higher scores indicating better function)
Change in telomere length in skeletal muscles and whole blood
Assessed by Q-PCR
Change in mood
Assessed by geriatric depression scale (score range: 0 to 30, where lower scores indicating better mood)
Change in serum osteocalcin
Assessed by ELISA
Changed in concentration of targeted metabolites
Assessed by liquid chromatography hyphenated with mass spectrometry techniques
Change in serum procollagen type 1 N propeptide
Assessed by radioimmunoassay
Change in serum sclerostin
Assessed by ELISA
Change in serum 25-OH vitamin D
Assessed by immunoassay
Change in serum parathyroid hormone
Assessed by immunoassay
Change in serum Interleukin 6
Assessed by immunoassay
Change in Tumor necrosis factor
Assessed by immunoassay
Change in high-sensitivity c-reactive protein
Assessed by immunoassay
Change in p16
Assessed by immunohistochemistry
Change in p21
Assessed by immmnohistochemistry
Change in satellite cells
Assessed by by immunofluorescence
Change in fiber cross sectional area
Assessed by immunohistochemistry
Change in fiber type-specific response
Assessed by immunofluorescence
Change in gene expression of senescence associated secretory phenotype
Assessed by RT-PCR
Change in protein expression of senescence associated secretory phenotype
Assessed by western blotting
Change in Medical Outcomes 36-Item short form Health survey (SF-36)
Assessed by Physical component summary and mental component summary score (score range 0 to 100, with higher scores indicating better health status)
Change in Impact of Weight on Quality of Life_Lite (IWQOL-lite) score
Assessed by IWQO-liteL questionnaire
Change in serum adiponectin
Assessed by ELISA
Change in serum leptin
Assessed by ELISA
Change in fasting serum insulin
Assessed by immunoassay
Change in fasting serum glucose
Assessed by glucose oxidase method
Change in blood pressure
Assessed by sphygmonanometry
Change in serum lipids
Assessed by automated enzymatic/colorimetric assays
Change in insulin growth factor 1
Assessed by immunoassay
Change in Cognitive composite scores
Using cognitive toolbox which yields the following summary scores: Cognitive Function Composite Score, Fluid Cognition Composite Score, and Crystallized Cognition Composite Score (score range: -3 to +3 for each with higher scores indicating better cognitive status
Change in habitual physical activity assessed by questionnaires
Using the Stanford physical activity questionnaire (score range: 0 to 40 with higher scores indicating higher physical activity levels)
Change in habitual physical activity measured objectively
Using accelerometers

Full Information

First Posted
January 2, 2020
Last Updated
February 2, 2023
Sponsor
VA Office of Research and Development
Collaborators
Michael E. DeBakey VA Medical Center, Baylor College of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04221750
Brief Title
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
Acronym
DEMFOS
Official Title
Lifestyle Intervention Plus Metformin to Treat Frailty in Older Veterans With Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 14, 2021 (Actual)
Primary Completion Date
September 30, 2025 (Anticipated)
Study Completion Date
September 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
Collaborators
Michael E. DeBakey VA Medical Center, Baylor College of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The continuing increase in prevalence of obesity in older adults including many older Veterans has become a major health concern. The clinical trial will test the central hypothesis that a multicomponent intervention consisting of lifestyle therapy (diet-induced weight loss and exercise training) plus metformin will be the most effective strategy for reversing sarcopenic obesity and frailty in older Veterans with obesity.
Detailed Description
The growing prevalence of obesity in older adults including many older Veterans, has become a major concern in the US already strained health care system in general and in the VA in particular. In older adults, obesity exacerbates the age-related decline in physical function resulting in frailty, decrease in quality of life, loss of independence, and increase in nursing home admissions. The investigators' group demonstrated that weight loss from lifestyle therapy improves physical function and ameliorates frailty but the improvement was modest at best and most obese older adults remained frail. More importantly, there are concerns that the weight-loss induced loss of muscle and bone mass could worsen underlying age-related sarcopenia and osteopenia in the subset of frail obese elderly. Metformin, a biguanide, is a widely available drug used as first line treatment of type 2 diabetes. Animal studies suggest that metformin improves health span and increases lifespan, hence may represent a novel intervention for frailty. Because metformin reduces cellular senescence and senescence-associated phenotype (SASP), it is believed to retard accelerated aging most especially in older adults with obesity. The objective is to conduct a head-head comparative efficacy, placebo controlled, randomized controlled trial to test the hypothesis that lifestyle therapy + metformin for six months will be more effective than lifestyle therapy alone or metformin alone in improving physical function and preventing the weight loss-induced reduction in muscle and bone mass in obese (BMI > 30 kg/m2) older (age 65 years) Veterans with physical frailty.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frailty, Sarcopenic Obesity, Aging

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Placebo controlled
Allocation
Randomized
Enrollment
114 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lifestyle Therapy plus Metformin
Arm Type
Experimental
Arm Description
Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
Arm Title
Lifestyle Therapy plus Placebo
Arm Type
Placebo Comparator
Arm Description
Diet-induced weight loss and Exercise Training plus Placebo
Arm Title
Healthy lifestyle plus Metformin
Arm Type
Active Comparator
Arm Description
Healthy lifestyle and Metformin 1 gm bid
Intervention Type
Behavioral
Intervention Name(s)
Lifestyle therapy
Other Intervention Name(s)
Diet-induced weight loss and exercise training
Intervention Description
Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
Intervention Type
Drug
Intervention Name(s)
Metformin Hydrochloride
Intervention Description
Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
Intervention Type
Behavioral
Intervention Name(s)
Healthy Lifesylte
Intervention Description
Group educational sessions that focus on healthy diet, exercise, and social support once a month
Primary Outcome Measure Information:
Title
Change in the modified Physical Performance Test (PPT)
Description
The Physical Performance Test includes seven standardized tasks (walking 15.2 m [50 ft], putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg test) plus two additional tasks (going up and down four flights of stairs and making a 360-degree turn). The score for each task ranges from 0 to 4, with higher scores indicating better physical performance; a perfect score would be 36.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Change in muscle strength
Description
Assessed by biodex dynamometer and1-repetition maximum
Time Frame
6 months
Title
Change in dynamic balance
Description
Assessed by the obstacle course
Time Frame
6 months
Title
Change in static balance
Description
Assessed by one leg stance
Time Frame
6 months
Title
Change in gait speed
Description
Assessed by time need to walk 25 ft
Time Frame
6 months
Title
Change in peak aerobic power
Description
Assessed by indirect calorimetry during a graded exercise test
Time Frame
6 months
Title
Change in lean body mass
Description
Assessed by dual-energy x-ray absorptiometry (DXA)
Time Frame
6 months
Title
Chang in body fat
Description
Assessed by DXA
Time Frame
6 months
Title
Change in thigh muscle
Description
Assessed by magnetic resonance imaging (MRI)
Time Frame
6 months
Title
Change in thigh fat
Description
Assessed by MRI
Time Frame
6 months
Title
Change in muscle quality
Description
Assessed by ratio of skeletal strength per unit of skeletal muscle
Time Frame
6 months
Title
Change in bone microarchitecture
Description
Assessed by high-resolution peripheral quantitative computed tomograph (HR-pQCT)
Time Frame
6 months
Title
Change in bone strength
Description
Assessed by finite-element analyses
Time Frame
6 months
Title
Change in hip, lumbar spine, and wrist bone mineral density (BMD)
Description
Assessed by DXA
Time Frame
6 months
Title
Change in wrist and tibial cortical and trabecular BMD
Description
Assessed by HR-pQCT
Time Frame
6 months
Title
Change in serum C-telopeptide
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in subjective ability to function
Description
Assessed by Functional Status Questionnaire (score range: 0 to 36 with higher scores indicating better function)
Time Frame
6 months
Title
Change in telomere length in skeletal muscles and whole blood
Description
Assessed by Q-PCR
Time Frame
6 months
Title
Change in mood
Description
Assessed by geriatric depression scale (score range: 0 to 30, where lower scores indicating better mood)
Time Frame
6 months
Title
Change in serum osteocalcin
Description
Assessed by ELISA
Time Frame
6 months
Title
Changed in concentration of targeted metabolites
Description
Assessed by liquid chromatography hyphenated with mass spectrometry techniques
Time Frame
6 months
Title
Change in serum procollagen type 1 N propeptide
Description
Assessed by radioimmunoassay
Time Frame
6 months
Title
Change in serum sclerostin
Description
Assessed by ELISA
Time Frame
6 months
Title
Change in serum 25-OH vitamin D
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in serum parathyroid hormone
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in serum Interleukin 6
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in Tumor necrosis factor
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in high-sensitivity c-reactive protein
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in p16
Description
Assessed by immunohistochemistry
Time Frame
6 months
Title
Change in p21
Description
Assessed by immmnohistochemistry
Time Frame
6 months
Title
Change in satellite cells
Description
Assessed by by immunofluorescence
Time Frame
6 months
Title
Change in fiber cross sectional area
Description
Assessed by immunohistochemistry
Time Frame
6 months
Title
Change in fiber type-specific response
Description
Assessed by immunofluorescence
Time Frame
6 months
Title
Change in gene expression of senescence associated secretory phenotype
Description
Assessed by RT-PCR
Time Frame
6 months
Title
Change in protein expression of senescence associated secretory phenotype
Description
Assessed by western blotting
Time Frame
6 months
Title
Change in Medical Outcomes 36-Item short form Health survey (SF-36)
Description
Assessed by Physical component summary and mental component summary score (score range 0 to 100, with higher scores indicating better health status)
Time Frame
6 months
Title
Change in Impact of Weight on Quality of Life_Lite (IWQOL-lite) score
Description
Assessed by IWQO-liteL questionnaire
Time Frame
6 months
Title
Change in serum adiponectin
Description
Assessed by ELISA
Time Frame
6 months
Title
Change in serum leptin
Description
Assessed by ELISA
Time Frame
6 months
Title
Change in fasting serum insulin
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in fasting serum glucose
Description
Assessed by glucose oxidase method
Time Frame
6 months
Title
Change in blood pressure
Description
Assessed by sphygmonanometry
Time Frame
6 months
Title
Change in serum lipids
Description
Assessed by automated enzymatic/colorimetric assays
Time Frame
6 months
Title
Change in insulin growth factor 1
Description
Assessed by immunoassay
Time Frame
6 months
Title
Change in Cognitive composite scores
Description
Using cognitive toolbox which yields the following summary scores: Cognitive Function Composite Score, Fluid Cognition Composite Score, and Crystallized Cognition Composite Score (score range: -3 to +3 for each with higher scores indicating better cognitive status
Time Frame
6 months
Title
Change in habitual physical activity assessed by questionnaires
Description
Using the Stanford physical activity questionnaire (score range: 0 to 40 with higher scores indicating higher physical activity levels)
Time Frame
6 months
Title
Change in habitual physical activity measured objectively
Description
Using accelerometers
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI = or > 30 kg/m2 Stable body weight (plus/minus 2 kg) during the past 6 months Sedentary (regular exercise <1 h/wk or <2 x/wk for the last 6 months) Willing to provide informed consent Exclusion Criteria: Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, or use of metformin, in which exercise, dietary restrictions, or metformin are contraindicated, or that would interfere with interpretation of results Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstable disease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonary disease requiring steroid pills or the use of supplemental oxygen) that would contraindicate exercise or dietary restriction Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, active rheumatoid arthritis) disease or impairments that would contraindicate participation in exercise Renal impairment as defined by an estimated glomerular filtration rate (eGFR of less than 30 mL/min/1.73 m2) in which metformin is contraindicated Other significant co-morbid disease that would impair ability to participate in the exercise intervention (e.g. severe psychiatric disorder [e.g. bipolar, schizophrenia], excess alcohol use [>14 drinks per week]) Severe visual or hearing impairments that would interfere with following directions Significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State Exam (i.e. MMSE score <24)69 Uncontrolled hypertension (BP>160/90 mm Hg) History of malignancy during the past 5 years (except non-melanoma skin cancers) Current use of bone acting drugs (e.g. use of estrogen, or androgen containing compound,raloxifene, calcitonin, parathyroid hormone during the past year or bisphosphonates during the last two years) Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragility fractures Known history of diabetes mellitus or any of the following: fasting blood glucose of 126 mg/dl, 2-h blood glucose 200 mg/dl in the OGTT, or HbA1c of 6.5% or > Terminal illness with life expectancy less than 12 months, as determined by a physician Use of any drugs or natural products designed to induce weight loss within past three months History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men) Positive exercise stress test for ischemia or any indication for early termination of exercise stress testing Taking metformin or any other glucose lowering drug Lives outside of the study site or is planning to move out of the area in the next 2 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dennis T Villareal, MD
Phone
(713) 794-7151
Email
Dennis.Villareal@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Arjun Paudyal, MS
Phone
(713) 578-4300
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dennis T Villareal, MD
Organizational Affiliation
Michael E. DeBakey VA Medical Center, Houston, TX
Official's Role
Principal Investigator
Facility Information:
Facility Name
Michael E. DeBakey VA Medical Center, Houston, TX
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4211
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dennis T Villareal, MD
Phone
713-794-7151
Email
Dennis.Villareal@va.gov
First Name & Middle Initial & Last Name & Degree
Dennis T Villareal, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication (guidance is provided on the ORD website). MEDVAMC will not provide unrestricted, open public access to large scale health related datasets because of re-identification concerns and the obligation to protect Veterans' private information. However, controlled public access will be provided to the greatest extent possible under specific DUAs or other written agreements, and open access will be provided to the final datasets underlying peer-reviewed publications (aggregated data that can be released with privacy and confidentiality risks).

Learn more about this trial

Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors

We'll reach out to this number within 24 hrs